InspireMD, Inc.
InspireMD, Inc. develops and commercializes carotid stent systems used to treat carotid artery disease and help prevent stroke. The company is transitioning from a development-focused medical device business to a direct commercial model, with CGuard Prime as its lead product and a growing U.S. launch effort supported by manufacturing and distribution partners.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaImplantable stent products used in carotid artery interventions to reduce stroke risk.
Sales, training, market access and medical affairs support for product adoption.
Third-party manufacturing and production transfer activities supporting product supply.
Asiakkaat
InspireMD sells primarily to hospitals, interventional physicians and vascular specialists that perform carotid procedures. Demand is driven by clinical adoption, physician access, reimbursement coverage and the ability to demonstrate product benefits versus alternative treatment options.
Buy carotid stent systems for use in inpatient and outpatient vascular procedures.
Use and recommend the product based on clinical performance and ease of adoption.
Influence utilization through coverage and reimbursement decisions for carotid procedures.
May support U.S. launch, co-promotion and market access if direct commercialization is insufficient.
Strategia
The core strategy is to establish CGuard Prime in the U.S. market through a direct sales organization, distribution capability and clinical support infrastructure. At the same time, the company is diversifying manufacturing through a third-party partner to scale production and reduce execution risk as commercialization expands.
The U.S. market is the main growth opportunity and requires physician adoption, reimbursement and sales execution.
Commercial success depends on reliable production and the ability to meet demand without disrupting quality or supply.
If direct commercialization underperforms, collaboration can extend reach but may dilute economics.
Maantiede
Q1/2026The company is headquartered in Miami, Florida, but its operational footprint remains tied to Israel and the U.S. commercial build-out. Management has highlighted North Carolina contract manufacturing for CGuard Prime and exposure to Israel-related geopolitical and trade risks, which can affect supply continuity, costs and lead times.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
The business is highly execution-dependent because revenue growth relies on successfully launching CGuard Prime and building a sales force, distribution network and manufacturing base. It also faces meaningful geopolitical and trade exposure from Israel-related operations, plus the usual medical device risks around physician adoption, reimbursement, product liability and regulatory scrutiny.
- U.S. commercialization execution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company is investing heavily in direct sales, training and distribution, but adoption may lag expectations.
Kohdistuu: CGuard Prime launch in the United States
- Market acceptance and reimbursement riskVaikutus: KorkeaTodennäköisyys: Korkea
Physician adoption and third-party payor coverage determine procedure volumes and commercial success.
Kohdistuu: Carotid stent market
- Geopolitical exposure to IsraelVaikutus: KorkeaTodennäköisyys: Kohtalainen
Conflict, sanctions or disruption in Israel could affect operations, logistics and profitability.
Kohdistuu: Israeli operations and supply chain
- Manufacturing and supply chain dependenceVaikutus: KorkeaTodennäköisyys: Matala
Production is being transferred to a third-party manufacturer, creating quality, timing and capacity risk.
Kohdistuu: Aptyx contract manufacturing in North Carolina
- Trade policy and tariff riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Tariffs on medical devices or Israel-linked imports could increase cost of goods sold and reduce pricing flexibility.
Kohdistuu: U.S.-Israel trade flows
Kirjanpito
Harkinnanvaraiset erätTiming depends on shipment, acceptance and any co-promotion or distribution terms.
Vaikutus: Can shift revenue between quarters and affect comparability.
Production ramp and third-party manufacturing can create inventory valuation and cost absorption issues.
Vaikutus: Can affect gross margin and working capital.
Sales force, market access and launch costs are front-loaded relative to revenue generation.
Vaikutus: Can suppress near-term operating results.
Medical device businesses face claims and regulatory-related contingencies that require estimates.
Vaikutus: Can create earnings volatility if reserves change.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Inspire Medical Systems, Inc.
INSP · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea.
iRadimed Corporation
IRMD · Surgical & Medical Instruments & Apparatus
IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service.
Odyssey Health, Inc.
ODYY · Surgical & Medical Instruments & Apparatus
Lifeward Ltd.
LFWD · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Penumbra Inc
PEN · Surgical & Medical Instruments & Apparatus
Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body.
Päivitetty: 24.9.2026